SCHEMBL509423

SCHEMBL509423

NCc1cccc(C(N)=O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 2/20 0.66
PARP1 P09874 7/20 0.55
MEP1B Q16820 1/20 0.53
ENPP2 Q13822 1/20 0.52
FOLH1 Q04609 1/20 0.49
PLAU P00749 1/20 0.49
TSHR P16473 2/20 0.48
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
CYP2C19 P33261 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KLKB1 P03952 1/20 0.48
IDH1 O75874 1/20 0.48
CFD P00746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29364575 1.00 LOXL2 (0.66) LOXL2PARP1MEP1BENPP2FOLH1
SCHEMBL9842445 0.94 LOXL2 (0.58) LOXL2PARP1MEP1BENPP2PLAU
SCHEMBL172996 0.89 CFD (0.61) LOXL2PARP1CFD
Terephthalamide SCHEMBL9842226 0.88 PLA2G10 (0.57) LOXL2PARP1ENPP2PLAUTSHR
SCHEMBL14899838 0.85 CFD (0.66) LOXL2ENPP2KLKB1CFD
SCHEMBL27594322 0.85 LOXL2 (0.65) LOXL2ENPP2FOLH1CYP3A4TDP1
Benzamide SCHEMBL27536269 0.85 PARP1 (0.70) LOXL2PARP1TSHRPOLBCYP3A4
SCHEMBL17672270 0.85 PLA2G2A (0.59) PARP1MEP1BFOLH1TSHRPOLB
SCHEMBL8342426 0.84 TAAR1 (0.55) LOXL2PARP1MEP1BFOLH1NOS1
SCHEMBL31500915 0.83 FOLH1 (0.66) LOXL2ENPP2FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105229002-A BET protein inhibiting dihydropyridopyrazinones Bayer Pharma AG 2016-01-06 CN claimed
US-20100210516-A1 Growth Factor Binding Molecules UNIVERSITY OF SOUTH FLORIDA (US) 2010-08-19 US claimed
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-07-29 US claimed
EP-2188289-A2 (7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION Lexicon Pharmaceuticals, Inc. (US) 2010-05-26 EP claimed
WO-2009021169-A2 (7H-PYRR0L0 [2, 3-D] PYRIMIDIN-4-YL) -PIPERAZINES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATION LEXICON PHARMACEUTICALS, INC. (US) 2009-02-12 WO claimed
CN-100351228-C Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORP (KR) 2007-11-28 CN claimed
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-12-07 US claimed
CN-1839115-A Hydroxamic acid derivatives and preparation method thereof AMOREPACIFIC CORP (KR) 2006-09-27 CN claimed
US-20060084596-A1 Growth factor binding molecules UNIVERSITY OF SOUTH FLORIDA 2006-04-20 US claimed
EP-1417190-A1 SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR Amgen Inc. (US) 2004-05-12 EP claimed
WO-2003009850-A1 SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR AMGEN INC. (US) 2003-02-06 WO claimed
EP-1021435-A1 SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED THIOPHENES AND OF ARRAYS OF SUBSTITUTED THIOPHENES NOVO NORDISK A/S (DK) 2000-07-26 EP claimed
WO-1997040034-A1 SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED THIOPHENES AND OF ARRAYS OF SUBSTITUTED THIOPHENES NOVO NORDISK A/S (DK) 1997-10-30 WO claimed
EP-0400290-A1 5-Amino-4-hydroxyvalerianic acid derivatives useful as intermediates in the preparation of renin inhibitors CIBA-GEIGY AG (CH) 1990-12-05 EP claimed
US-4863903-A RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1989-09-05 US claimed
US-4719288-A HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1988-01-12 US claimed
EP-0143746-A2 5-Amino 4-hydroxy-valeryl-substituted derivatives CIBA-GEIGY AG (CH) 1985-06-05 EP claimed
US-20250179072-A1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2025-06-05 US disclosed
EP-0144290-A2 Substituted ethylenediamine derivatives CIBA-GEIGY AG (CH) 1985-06-12 EP disclosed
EP-0143746-A2 5-Amino 4-hydroxy-valeryl-substituted derivatives CIBA-GEIGY AG (CH) 1985-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210516-A1 Growth Factor Binding Molecules PDGFA, PGF, FLT1 LOXL2 2636/4885PARP1 2150/4885MEP1B 1677/4885
US-20060276496-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 LOXL2 1783/4885PARP1 2549/4885MEP1B 789/4885
US-20060084596-A1 Growth factor binding molecules PDGFA, PGF, FLT1 LOXL2 2636/4885PARP1 2150/4885MEP1B 1677/4885
US-20100190773-A1 Anti-Cytokine Heterocyclic Compounds MAPKAPK2, MAP4K2, MAP3K2 LOXL2 1783/4885PARP1 2549/4885MEP1B 789/4885
US-20250179072-A1 TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS AKR1C2, AKR1B1, AKR1C1 LOXL2 3757/4885PARP1 462/4885MEP1B 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.